Back | Next |
home / stock / imdz / imdz message board
Subject | By | Source | When |
---|---|---|---|
... Phase 2 study that showed the combination | willlbone | investorshub | 10/12/2018 1:54:26 PM |
Immune Design Nearing Critical Point In Valuation | stockguard | investorshub | 05/15/2018 8:42:50 PM |
https://charts.stocktwits.com/production/original 123535328.png | stockguard | investorshub | 05/15/2018 8:16:11 PM |
MoMo algo`s going to kick in. Breaking out | stockguard | investorshub | 05/15/2018 8:03:11 PM |
Immune Design Reports Data Update for Lead Immunotherapy | chmcnfunds | investorshub | 03/12/2018 12:59:35 PM |
Looks like it's heavily shorted. But still a | QServus | investorshub | 11/14/2017 2:47:09 PM |
Looks like the Dumping has stopped to me! | DTGoody | investorshub | 11/08/2017 7:50:14 PM |
It's going to run when dumping is done | QServus | investorshub | 11/02/2017 6:05:44 PM |
All these insiders buying shares kind of make | DTGoody | investorshub | 11/02/2017 1:31:12 PM |
Probably going to slowly bleed until next quarter. | willlbone | investorshub | 10/24/2017 7:42:32 PM |
Going to $3 - reload then | QServus | investorshub | 10/24/2017 5:09:43 PM |
Dilution and drug failure | willlbone | investorshub | 10/24/2017 4:55:17 PM |
Very! | QServus | investorshub | 10/23/2017 3:55:26 PM |
Bullish !! | Chuckx | investorshub | 10/23/2017 8:57:53 AM |
Churning at 5.20 like mad - crazy run | QServus | investorshub | 10/20/2017 7:53:54 PM |
Looks like bottom is in | QServus | investorshub | 10/20/2017 5:10:13 PM |
Break that resistance @ 6 and off to | QServus | investorshub | 10/20/2017 11:42:30 AM |
RBC upper their target on this from $20 | QServus | investorshub | 10/20/2017 12:46:05 AM |
Yea but $6 is almost hitting now after market | QServus | investorshub | 10/19/2017 8:52:35 PM |
Down 6 days in a row -50% | shurtha2000 | investorshub | 10/19/2017 8:50:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Immune Design (NASDAQ: IMDZ) at a purchase price of $5.85 per share. As of the tender...
HENDERSON, NV / ACCESSWIRE / February 22, 2019 / Below are several healthcare companies in the news leading the sector recently. A company in the sector that has not had news recently but according to their website, "has an open IND (Investigational New Drug) and has agreed with the FDA on a...
CORAL GABLES, FL / ACCESSWIRE / February 21, 2019 / The recent success of the healthcare stock market can be attributed to the fact that companies in the healthcare industry are looking into new innovative approaches and technologies to better improve their offerings for consumers. Whereas...